159 related articles for article (PubMed ID: 37426827)
1. ACSM6 overexpression indicates a non-inflammatory tumor microenvironment and predicts treatment response in bladder cancer: results from multiple real-world cohorts.
Li Z; Yao Y; Qi T; Wu Z; Deng D; Liu B
Front Pharmacol; 2023; 14():1222512. PubMed ID: 37426827
[No Abstract] [Full Text] [Related]
2. ACER2 forms a cold tumor microenvironment and predicts the molecular subtype in bladder cancer: Results from real-world cohorts.
Liu J; Cheng C; Qi T; Xiao J; Zhou W; Deng D; Dai Y
Front Genet; 2023; 14():1148437. PubMed ID: 36936425
[No Abstract] [Full Text] [Related]
3. GATA3 Predicts the Tumor Microenvironment Phenotypes and Molecular Subtypes for Bladder Carcinoma.
Zhang Q; Qi T; Long Y; Li X; Yao Y; Wu Q; Zou A; Qthmane B; Liu P
Front Surg; 2022; 9():860663. PubMed ID: 35647011
[TBL] [Abstract][Full Text] [Related]
4. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
[No Abstract] [Full Text] [Related]
5. CD93 orchestrates the tumor microenvironment and predicts the molecular subtype and therapy response of bladder cancer.
Zheng X; Xu H; Lin T; Tan P; Xiong Q; Yi X; Qiu S; Yang L; Shen B; Ai J; Wei Q
Comput Biol Med; 2022 Aug; 147():105727. PubMed ID: 35785664
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
Shi X; Peng X; Chen Y; Shi Z; Yue C; Zuo L; Zhang L; Gao S
Front Immunol; 2023; 14():1326509. PubMed ID: 38130721
[TBL] [Abstract][Full Text] [Related]
7.
Zhao X; Hu J; Li J; Gu L; Chen J; Othmane B; Gong G; Yuan J; Deng H
Dis Markers; 2022; 2022():7147279. PubMed ID: 35909893
[TBL] [Abstract][Full Text] [Related]
8. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.
Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y
Front Immunol; 2022; 13():965469. PubMed ID: 36090967
[TBL] [Abstract][Full Text] [Related]
9. IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer.
Yi X; Zheng X; Xu H; Li J; Zhang T; Ge P; Liao D; Li H; Lyu X; Ai J
Front Immunol; 2022; 13():898493. PubMed ID: 35812369
[TBL] [Abstract][Full Text] [Related]
10. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
Front Immunol; 2021; 12():725223. PubMed ID: 34484235
[TBL] [Abstract][Full Text] [Related]
11. A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer.
Liu Z; Qi T; Li X; Yao Y; Othmane B; Chen J; Zu X; Ou Z; Hu J
Front Immunol; 2021; 12():791924. PubMed ID: 34975891
[TBL] [Abstract][Full Text] [Related]
12. TNF Family-Based Signature Predicts Prognosis, Tumor Microenvironment, and Molecular Subtypes in Bladder Carcinoma.
Li H; Liu S; Li C; Xiao Z; Hu J; Zhao C
Front Cell Dev Biol; 2021; 9():800967. PubMed ID: 35174161
[No Abstract] [Full Text] [Related]
13. A novel platelet risk score for stratifing the tumor immunophenotypes, treatment responses and prognosis in bladder carcinoma: results from real-world cohorts.
Deng D; Li X; Qi T; Dai Y; Liu N; Li H
Front Pharmacol; 2023; 14():1187700. PubMed ID: 37214475
[No Abstract] [Full Text] [Related]
14. Eph receptor B6 shapes a cold immune microenvironment, inhibiting anti-cancer immunity and immunotherapy response in bladder cancer.
Jia X; Zhang D; Zhou C; Yan Z; Jiang Z; Xie L; Jiang J
Front Oncol; 2023; 13():1175183. PubMed ID: 37637034
[TBL] [Abstract][Full Text] [Related]
15. Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma.
Li H; Zu X; Hu J; Xiao Z; Cai Z; Gao N; Chen J
Front Immunol; 2022; 13():964393. PubMed ID: 36211344
[TBL] [Abstract][Full Text] [Related]
16. 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer.
Hu J; Othmane B; Yu A; Li H; Cai Z; Chen X; Ren W; Chen J; Zu X
BMC Med; 2021 Nov; 19(1):289. PubMed ID: 34836536
[TBL] [Abstract][Full Text] [Related]
17. An IFN-γ-related signature predicts prognosis and immunotherapy response in bladder cancer: Results from real-world cohorts.
Deng H; Deng D; Qi T; Liu Z; Wu L; Yuan J
Front Genet; 2022; 13():1100317. PubMed ID: 36685901
[TBL] [Abstract][Full Text] [Related]
18. Molecular vasculogenic mimicry-Related signatures predict clinical outcomes and therapeutic responses in bladder cancer: Results from real-world cohorts.
Zhang C; Xiao J; Yuan T; He Y; Deng D; Xiao Z; Chen J; Zu X; Liu P; Liu Z
Front Pharmacol; 2023; 14():1163115. PubMed ID: 37197406
[TBL] [Abstract][Full Text] [Related]
19. Tumor Microenvironment Analysis Identified Subtypes Associated With the Prognosis and the Tumor Response to Immunotherapy in Bladder Cancer.
Zhang H; Song J; Dong J; Liu Z; Lin L; Wang B; Ma Q; Ma L
Front Genet; 2021; 12():551605. PubMed ID: 33732281
[No Abstract] [Full Text] [Related]
20. A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer.
Cai Y; Cheng Y; Wang Z; Li L; Qian Z; Xia W; Yu W
BMC Cancer; 2023 Aug; 23(1):725. PubMed ID: 37543645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
